ALEC Stock Analysis: Buy, Sell, or Hold?
ALEC - Alector, Inc. Common Stock
$2.16
-0.01 (-0.23%)
▼
5d:
+5.12%
30d:
-16.15%
90d:
+9.39%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Accumulation
ALEC is down 5.7% this week, but smart money is accumulating calls. Top strike: $2.5 2026-06-18 with 8 OI. Call ratio: 100% View Scanner →
Strength: 7.9/10
Get Alerted When ALEC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ALEC shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: ALEC shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: ALEC is currently trading at $2.15, which is considered oversold relative to its 30-day fair value range of $2.22 to $2.54.
Technical Outlook: Technically, ALEC is in a strong uptrend. Immediate support is located at $2.00, while resistance sits at $2.70.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.10 (+43.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALEC is in a strong uptrend. Immediate support is located at $2.00, while resistance sits at $2.70.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.10 (+43.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.22 -
$2.54
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.5% below Wall St target ($3.10)
Trading Range Analysis
30-Day Trading Range
$2.22 -
$2.54
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.27
(12.4%)
Support & Resistance Levels
Support Level
$2.01
Resistance Level
$2.70
Current Trend
Strong Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.91
Wall Street Target
$3.10
(+43.5%)
Revenue Growth (YoY)
-71.5%
Earnings Growth (YoY)
-86.3%
Share & Embed Analysis
Last updated: May 18, 2026 1:12 PM ET
Data refreshes hourly during market hours. Next update: 2:12 PM
Data refreshes hourly during market hours. Next update: 2:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALEC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Grace Wong-Sarad
SELL
1820 shares
2026-04-16
Grace Wong-Sarad
SELL
1000 shares
2026-03-10
Grace Wong-Sarad
SELL
4079 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 60 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 42 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 59 HOLD |
